跳至主要内容
临床试验/NCT00891592
NCT00891592已完成1 期

A Phase 1 Dose Escalation Study of Infusion of ex Vivo cd3/cd28 Costimulated Umbilical Cord Blood-derived t Cells in Adults Undergoing Transplantation for Advanced Hematologic Malignancies

University of Pennsylvania2 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
5
试验地点
2
主要终点
Dose limiting toxicity (DLT) is defined as grade 4 acute GVHD within the first 90 days following infusion.

研究概览

简要总结

This protocol will enroll subjects with advanced hematologic malignancies who do not have a suitable related or unrelated donor to undergo a Stem Cell Transplant.

In this study, subjects will undergo a Stem Cell Transplant using Cord Blood. Part of the cord blood will be used for the Stem Cell Transplant and part of the cord blood will be sent to a laboratory in order to grow the T cells (from the cord blood) and increase the activity of the cord blood T cells.

The purpose of this part of the study is to see if it is safe to give study subjects activated T cells made from a small portion of their donor UCB unit immediately after the UCB transplant. Activated T cells have been used safely in stem cell transplantation studies in the past, but they have never been studied UCB transplantation.

详细描述

The main study intervention includes CD3/CD28 ex vivo costimulated T cells derived from a thawed umbilical cord blood unit, co-infused following a myeloablative conditioning regimen.

Activated T cells are T cells that have been activated in the laboratory by exposure to 2 compounds or molecules called CD3 and CD28; when T cells are exposed to both of these compounds at the same time, they become activated or "stimulated" and may be more effective in fighting infections, cancer cells, and promoting the recovery of red cells, white cells, and platelets after transplantation. At the Hospital of the University of Pennsylvania, activated T cells are prepared at the Clinical Cell and Vaccine Production Facility, also known as the CVPF.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Subject is pregnant or lactating.
  • Subject has an uncontrolled infection.
  • Subject has an active or untreated disease involving the central nervous system.
  • Subject has an active or uncontrolled medical condition that would preclude participation in the protocol.

结局指标

主要结局

Dose limiting toxicity (DLT) is defined as grade 4 acute GVHD within the first 90 days following infusion.

时间窗: 90 Days post Transplant

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验